# Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial

> **NCT04177602** · PHASE1,PHASE2 · TERMINATED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 10 (actual)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **COMBINATION_PRODUCT:** Trifluridine/tipiracil chemoradiation
- **COMBINATION_PRODUCT:** Capecitabine based chemoradiation

## Key facts

- **NCT ID:** NCT04177602
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-04
- **Primary completion:** 2022-09-02
- **Final completion:** 2022-09-02
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to the amended therapy strategies for rectal cancer recently, it was decided not to transfer the study to the phase II part, as superiority over standard chemoradiation and transfer to a new therapy standard are increasingly unlikely.
- **Last updated:** 2023-02-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04177602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04177602, "Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04177602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*